SK Bioscience applies for rolling review of GBP510 in Britain

Home > Business > Industry

print dictionary print

SK Bioscience applies for rolling review of GBP510 in Britain

SK Bioscience researchers conduct tests at the company's lab. [SK BIOSCIENCE]

SK Bioscience researchers conduct tests at the company's lab. [SK BIOSCIENCE]

SK Bioscience said Wednesday it applied with Britain's Medicines and Healthcare products Regulatory Agency (MHRA) for a rolling review for GBP510, its Covid-19 vaccine candidate.
 
The rolling review enables the MHRA to begin an independent assessment of the vaccine using the results of Phase 1 and 2 clinical trials submitted by SK Bioscience. It reduces the time needed to get formal marketing authorization of the vaccine candidate.
 
The candidate is currently in global Phase 3 clinical trials. Marketing could begin in the first half.
 
Starting with the MHRA, SK Bioscience is planning to submit an application to European Medicines Agency, as well as apply for emergency use approval from World Health Organization in the first half.

BY SARAH CHEA [chea.sarah@joongang.co.kr]
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
s
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)